Autologous Bone Marrow Stem Cell Transplantation in Patients With Subacute Spinal Cord Injury

The aim of this study is to evaluate the efficacy and safety of intrathecal administration of autologous mesenchymal stem cells in participants with subacute spinal cord injury.

Inclusion Criteria:Both sexes over 18 years old;Closed or open spinal cord injury at the thoracic or lumbar level in the subacute phase (between 3 and 6 months after the event);ASIA A rating.Exclusion Criteria:Section of the spinal anatomy;Active infectious diseases;Terminal patients;Neurodegenerative diseases;Primary hematologic diseases;Bone reflecting increased risk for spinal puncture;Coagulopathies;Hepatic dysfunction;Pregnancy;Other medical complications that contraindicate surgery, including major respiratory complications;Participation in another clinical trial;Use of metal implants close to vascular structures (such as cardiac pacemaker or prosthesis) that contraindicate magnetic resonance